Szomatosztatinreceptor-ligandok helye az acromegalia kezelésé ben

Translated title of the contribution: Role of somatostatin receptor ligands in the treatment of acromegaly - Review of literature

Orsolya Nemes, E. Mezősi

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Acromegaly is a rare disease with typical clinical manifestations. Untreated acromegaly carries a 2-4-fold increase in mortality in long-term outcome. The goal of treatment is double, including biochemical control of the disease (normalization of serum IGF1 levels compared to age and gender matched controls, GH levels below 1 ng/ml after oral glucose load, or random GH below 2.5 ng/ml) and control of the tumor mass. The therapeutic modalities currently available for the treatment of acromegaly are: surgery, medical therapy, radiation therapy and their combinations. The cornerstones of medical therapy in acromegaly are the somatostatin receptor ligands due to their effectiveness in controlling GH excess in 60-70 % of patients and their beneficial effects on tumor volume. Somatostatin analogues have an established role as adjuvant therapy after non-curative surgery, and evidence suggests their use as primary treatment for selected patients. The long-term use of somatostatin receptor ligands is safe and they are well tolerated. Future medical therapy consists of pasireotide, a novel, universal somatostatin receptor agonist, and a new class of drugs named dopastatins. The latter so-called chimeric molecules have strong affinity for somatostatin receptors and dopamine-2 receptors, resulting in a more effective blocking of GH secretion, according to preliminary data. The authors of this paper review the current medical therapy of acromegaly, focusing on the role of somatostatin receptor ligands.

Original languageHungarian
Pages (from-to)715-721
Number of pages7
JournalOrvosi Hetilap
Volume152
Issue number18
DOIs
Publication statusPublished - May 1 2011

Fingerprint

Somatostatin Receptors
Acromegaly
Ligands
Therapeutics
Dopamine Receptors
Rare Diseases
Somatostatin
Tumor Burden
Radiotherapy
Glucose
Mortality

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Szomatosztatinreceptor-ligandok helye az acromegalia kezelésé ben. / Nemes, Orsolya; Mezősi, E.

In: Orvosi Hetilap, Vol. 152, No. 18, 01.05.2011, p. 715-721.

Research output: Contribution to journalArticle

@article{ccb7c01ad4224f32a7948df5908cc56e,
title = "Szomatosztatinreceptor-ligandok helye az acromegalia kezel{\'e}s{\'e} ben",
abstract = "Acromegaly is a rare disease with typical clinical manifestations. Untreated acromegaly carries a 2-4-fold increase in mortality in long-term outcome. The goal of treatment is double, including biochemical control of the disease (normalization of serum IGF1 levels compared to age and gender matched controls, GH levels below 1 ng/ml after oral glucose load, or random GH below 2.5 ng/ml) and control of the tumor mass. The therapeutic modalities currently available for the treatment of acromegaly are: surgery, medical therapy, radiation therapy and their combinations. The cornerstones of medical therapy in acromegaly are the somatostatin receptor ligands due to their effectiveness in controlling GH excess in 60-70 {\%} of patients and their beneficial effects on tumor volume. Somatostatin analogues have an established role as adjuvant therapy after non-curative surgery, and evidence suggests their use as primary treatment for selected patients. The long-term use of somatostatin receptor ligands is safe and they are well tolerated. Future medical therapy consists of pasireotide, a novel, universal somatostatin receptor agonist, and a new class of drugs named dopastatins. The latter so-called chimeric molecules have strong affinity for somatostatin receptors and dopamine-2 receptors, resulting in a more effective blocking of GH secretion, according to preliminary data. The authors of this paper review the current medical therapy of acromegaly, focusing on the role of somatostatin receptor ligands.",
keywords = "acromegaly, dopastatin, growth hormone, pasireotide, somatostatin receptor ligands",
author = "Orsolya Nemes and E. Mezősi",
year = "2011",
month = "5",
day = "1",
doi = "10.1556/OH.2011.29102",
language = "Hungarian",
volume = "152",
pages = "715--721",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "18",

}

TY - JOUR

T1 - Szomatosztatinreceptor-ligandok helye az acromegalia kezelésé ben

AU - Nemes, Orsolya

AU - Mezősi, E.

PY - 2011/5/1

Y1 - 2011/5/1

N2 - Acromegaly is a rare disease with typical clinical manifestations. Untreated acromegaly carries a 2-4-fold increase in mortality in long-term outcome. The goal of treatment is double, including biochemical control of the disease (normalization of serum IGF1 levels compared to age and gender matched controls, GH levels below 1 ng/ml after oral glucose load, or random GH below 2.5 ng/ml) and control of the tumor mass. The therapeutic modalities currently available for the treatment of acromegaly are: surgery, medical therapy, radiation therapy and their combinations. The cornerstones of medical therapy in acromegaly are the somatostatin receptor ligands due to their effectiveness in controlling GH excess in 60-70 % of patients and their beneficial effects on tumor volume. Somatostatin analogues have an established role as adjuvant therapy after non-curative surgery, and evidence suggests their use as primary treatment for selected patients. The long-term use of somatostatin receptor ligands is safe and they are well tolerated. Future medical therapy consists of pasireotide, a novel, universal somatostatin receptor agonist, and a new class of drugs named dopastatins. The latter so-called chimeric molecules have strong affinity for somatostatin receptors and dopamine-2 receptors, resulting in a more effective blocking of GH secretion, according to preliminary data. The authors of this paper review the current medical therapy of acromegaly, focusing on the role of somatostatin receptor ligands.

AB - Acromegaly is a rare disease with typical clinical manifestations. Untreated acromegaly carries a 2-4-fold increase in mortality in long-term outcome. The goal of treatment is double, including biochemical control of the disease (normalization of serum IGF1 levels compared to age and gender matched controls, GH levels below 1 ng/ml after oral glucose load, or random GH below 2.5 ng/ml) and control of the tumor mass. The therapeutic modalities currently available for the treatment of acromegaly are: surgery, medical therapy, radiation therapy and their combinations. The cornerstones of medical therapy in acromegaly are the somatostatin receptor ligands due to their effectiveness in controlling GH excess in 60-70 % of patients and their beneficial effects on tumor volume. Somatostatin analogues have an established role as adjuvant therapy after non-curative surgery, and evidence suggests their use as primary treatment for selected patients. The long-term use of somatostatin receptor ligands is safe and they are well tolerated. Future medical therapy consists of pasireotide, a novel, universal somatostatin receptor agonist, and a new class of drugs named dopastatins. The latter so-called chimeric molecules have strong affinity for somatostatin receptors and dopamine-2 receptors, resulting in a more effective blocking of GH secretion, according to preliminary data. The authors of this paper review the current medical therapy of acromegaly, focusing on the role of somatostatin receptor ligands.

KW - acromegaly

KW - dopastatin

KW - growth hormone

KW - pasireotide

KW - somatostatin receptor ligands

UR - http://www.scopus.com/inward/record.url?scp=79955056456&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955056456&partnerID=8YFLogxK

U2 - 10.1556/OH.2011.29102

DO - 10.1556/OH.2011.29102

M3 - Article

C2 - 21498160

AN - SCOPUS:79955056456

VL - 152

SP - 715

EP - 721

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 18

ER -